Posted by Michael Wonder on 28 Jun 2020
Chiasma announces FDA approval of Mycappsa (octreotide) capsules, the first and only oral somatostatin analogue
26 June 2020 - Mycappsa is indicated for long-term maintenance treatment in acromegaly patients who have responded to and tolerated treatment with octreotide or lanreotide.
Chiasma announced today that the U.S. Food and Drug Administration approved Mycappsa (octreotide) capsules for long-term maintenance treatment in acromegaly patients who have responded to and tolerated treatment with octreotide or lanreotide.
Mycappsa is the first and only oral somatostatin analogue approved by the FDA and the first product approved by the FDA utilizing Chiasma’s Transient Permeability Enhancer technology.
